BioMarin Pharmaceutical (MEX:BMRN) Long-Term Debt: MXN25,792 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BMRN BioMarin Pharmaceutical Inc MEX:BMRN
80 GF Score
Price MXN959.00
GF Value MXN1,420.64
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Long-Term Debt?

BioMarin Pharmaceutical MEX:BMRN 80 Long-Term Debt is MXN25,792 Mil as of Mar. 2026. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,420.64 (Significantly Undervalued). The stock has 3 warning signs investors should review.

BioMarin Pharmaceutical's Long-Term Debt for the quarter that ended in Mar. 2026 was MXN25,792 Mil.

BioMarin Pharmaceutical's quarterly Long-Term Debt declined from Sep. 2025 (MXN10,945 Mil) to Dec. 2025 (MXN10,753 Mil) but then increased from Dec. 2025 (MXN10,753 Mil) to Mar. 2026 (MXN25,792 Mil).

BioMarin Pharmaceutical's annual Long-Term Debt increased from Dec. 2023 (MXN10,067 Mil) to Dec. 2024 (MXN12,412 Mil) but then declined from Dec. 2024 (MXN12,412 Mil) to Dec. 2025 (MXN10,753 Mil).

BioMarin Pharmaceutical  (MEX:BMRN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BioMarin Pharmaceutical Long-Term Debt Related Terms

BioMarin Pharmaceutical Long-Term Debt Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Long-Term Debt Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22,136.19 21,114.54 10,067.34 12,412.02 10,752.57

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12,185.93 11,225.25 10,945.31 10,752.57 25,791.85
MEX:BMRN
80GF Score
BioMarin Pharmaceutical Inc MEX:BMRN
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of MXN25,792 Mil mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Long-Term Debt of MXN25,792 Mil as of Mar. 2026.
Is BioMarin Pharmaceutical's Long-Term Debt too high?
BioMarin Pharmaceutical's current Long-Term Debt is MXN25,792 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Long-Term Debt compare to CYTK and ARWR?
BioMarin Pharmaceutical's Long-Term Debt of MXN25,792 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. BioMarin Pharmaceutical's current Long-Term Debt is MXN25,792 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,420.64, compared to a current price of MXN959.00 — trading 32.5% below its estimated fair value. The current Long-Term Debt is MXN25,792 Mil. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Long-Term Debt is MXN25,792 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of MXN959.00 is trading 32.5% below its estimated GF Value™ of MXN1,420.64. GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.

Key valuation signals for MEX:BMRN:

  • Long-Term Debt: MXN25,792 Mil
  • GF Value™: MXN1,420.64 vs. price of MXN959.00 (32.5% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score

Get the complete analysis for MEX:BMRN

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN959.00
Price
MXN1,420.64
GF Value